Mashawnda Dowell

A substudy of the PLATO trial reveals that treatment with ticagrelor reduces cardiovascular death, myocardial infarction, and stroke in some patients with non-ST-elevation acute coronary syndrome.

Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.

Results from a substudy of the PLATO trial show that patients with extensive CAD and high rates of recurrent cardiovascular events, death, and bleeding may benefit from treatment with ticagrelor.

Study results presented at the American Heart Association 2012 Scientific Sessions show that visible signs of aging such as baldness and yellow fatty deposits around the eye are predictors for heart attack and heart disease risk.

Many young adults age 18-24 with high blood pressure remain undiagnosed with hypertension, even after long-term physician care.

New research presented at the American Heart Association 2012 Scientific Sessions reveals that although the number of cardiovascular-related deaths increases during the winter months in the US, the rate increase is consistent across climates.

Results from the UMPIRE study show that use of fixed-dose combination cardiovascular drugs improve medication adherence and improve blood pressure and cholesterol levels in patients.

Results from the OPERA trial presented at AHA 2012 show that short-term use of fish oil supplements does not decrease post-operative atrial fibrillation.

Men age 50 and older who take multivitamins every day gain no added protection against heart attacks, stroke, or cardiovascular death.

A new experimental device may be able to use converted energy from a patient's heart to generate enough electricity to fully power a pacemaker.

Study results presented at AHA 2012 indicate that revascularization using CABG in diabetic patients with multivessel disease provides better clinical outcomes than PCI and is more cost effective in the long run.

Results from a sub-study of the Trial to Assess Chelation Therapy (TACT) that focused on quality of life issues in patients who had previously suffered a heart attack and were treated with chelation therapy reveal no improvements in these patients' quality of life.